Chloroquine vs Atovaquone Oral Suspension — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Antimalarial

Chloroquine

First FDA approval: 2011-07-01

Antimalarial

Atovaquone Oral Suspension

Brand: ATOVAQUONE

First FDA approval: 2024-07-08

Lowest NADACAcquisition cost floor across all NDCs

$2.48Per unit

$0.719Per unit

Average NADACAcross all dosage forms and strengths

$4.66Up to $5.76

$0.719Up to $0.719

Generic manufacturersActive ANDA holders — FDA Orange Book

45 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$591313Full year

—Full year

Part D claims (CY24)Total fills, all strengths

5K3K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$114Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes4 manufacturers

NoBrand-only